A druggable redox switch on SHP1 controls macrophage inflammation

This study utilizes deep redox proteomics to identify a druggable redox switch at Cys102 on the immune regulator SHP1, enabling the development of a selective covalent agonist that activates SHP1 to suppress macrophage inflammation.

The Gist

The Big Picture: Finding the "Off" Switch for Inflammation

Imagine your body's immune system is like a massive, high-tech security team. Its job is to protect you from invaders like bacteria and viruses. However, sometimes this security team gets a little too excited. It starts shouting (releasing inflammatory chemicals) even when there isn't a real emergency. This is what happens in autoimmune diseases like Rheumatoid Arthritis or Multiple Sclerosis, and it causes pain and damage.

For a long time, scientists have struggled to find a way to tell this security team to "calm down" without turning off their ability to fight real enemies. Most drugs try to block the bad signals, but this paper introduces a new strategy: finding a hidden "On" switch for the body's natural "brakes."

The Discovery: A Map of Chemical "Dials"

The researchers started by looking at the immune system's proteins. They knew that these proteins have special parts called cysteines (think of them as tiny, sensitive dials or knobs on a machine). These dials can be turned by the body's natural chemistry (specifically, oxidation, which is like a tiny bit of rust or a spark).

• The Problem: We didn't know which dials controlled which functions.
• The Solution: The team created a massive digital map called OxImmune. They looked at thousands of immune proteins and found 788 specific dials that change their position depending on the body's environment.

Think of this map like a treasure map for drug developers. Instead of guessing where to look, they now have a list of 788 "druggable" spots where they could potentially attach a medicine to change how a protein works.

The Star Player: SHP1 (The Body's Brake Pedal)

Among all the proteins they studied, they focused on one called SHP1.

• The Analogy: If the immune system is a car speeding toward a cliff (inflammation), SHP1 is the brake pedal.
• The Problem: In many disease states, the brake pedal is stuck in the "off" position. The car (immune system) keeps speeding, causing a crash (chronic inflammation).
• The Goal: The researchers wanted to find a way to unstick the brake and press it down.

The Breakthrough: A "Key" for a Hidden Lock

The researchers discovered a specific spot on the SHP1 brake pedal called Cys102.

• The Lock: This spot is like a hidden lock on the brake pedal. When the body is under stress (like an infection), this lock gets "oxidized" (the key turns), and the brake gets stuck.
• The Key: The team designed a tiny, custom-made molecule called SCA (specifically SCA1 and its improved versions).
• How it Works: The SCA molecule is shaped perfectly to fit into that hidden lock (Cys102). When it clicks in, it doesn't just jam the lock; it actually forces the brake pedal to release. It pushes the protein from a "stuck" state into an "active" state.

The Results: Calming the Storm

When they tested this new "key" (SCA) on immune cells (macrophages) in a dish:

1. It was precise: It only touched the SHP1 brake pedal and ignored all other proteins (no accidental side effects).
2. It worked fast: It immediately stopped the cells from shouting inflammatory chemicals.
3. It worked on real patients: They tested it on cells taken from patients with Rheumatoid Arthritis and Multiple Sclerosis. Even in these sick cells, the "key" worked to turn down the inflammation.

Why This Matters

This paper is a two-part victory:

1. The Map: They gave the world a new map (OxImmune) showing exactly where to look for new medicines in the immune system.
2. The Proof: They proved that you can use this map to build a drug that acts as a positive activator. Instead of just blocking a bad process (which is like putting tape over a gas pedal), they found a way to turn on the body's own natural healing brakes.

In summary: The scientists found a hidden switch on the immune system's "brake pedal," built a tiny key to flip that switch, and successfully stopped the immune system from overreacting. This opens the door for a new generation of drugs that could treat autoimmune diseases by helping the body calm itself down.

Technical Summary

1. The Problem

• Undrugged Immune Targets: While immunological proteins are major disease targets, many remain "undrugged," particularly protein phosphatases like SHP1, which are difficult to target with positive allosteric modulators.
• Lack of Redox Mechanism Knowledge: Reactive oxygen species (ROS) and redox-active metabolites regulate immune cell function (e.g., macrophage cytokine production) via covalent modification of cysteine residues. However, there is a persistent lack of rigorous, systematic data identifying which specific cysteine residues on immune proteins are redox-regulated in vivo and how these modifications mechanistically control protein function.
• Therapeutic Gap: There is a need for a strategy to systematically discover these redox-regulated sites and develop small molecules that can exploit them for therapeutic intervention, specifically to activate (agonize) rather than just inhibit immune regulators.

2. Methodology

The authors employed a multi-disciplinary approach combining deep proteomics, chemical biology, structural biology, and cell physiology:

• OxImmune Resource Development:
  • Leveraged the existing Oximouse dataset (quantitative redox proteomics across 10 mouse tissues) to profile ~34,000 unique cysteines.
  • Focused on the InnateDB list of 1,125 innate immune proteins.
  • Defined "dynamic redox states" as cysteines exhibiting >10% difference in oxidation status between tissue conditions.
  • Annotated these sites against functional domains (kinases, phosphatases, etc.) and structural data (PDB/AlphaFold) to create the OxImmune compendium.
• Target Identification (SHP1):
  • Identified Cys102 on the immune regulator SHP1 (a key inhibitor of autoimmunity) as a dynamically redox-regulated site located in a pocket near the N-SH2 domain, involved in the transition from auto-inhibited to active states.
  • Validated Cys102 redox sensitivity in human THP-1 macrophages using LPS (oxidative stress) and reducing agents (NAC, tmTCEP).
• Chemical Probe Discovery (CPT-MS):
  • Used Cysteine-reactive Phosphate Tag Mass Spectrometry (CPT-MS) to screen cysteine-reactive small molecules against the proteome of human and mouse macrophages.
  • Identified SCA1, a covalent small molecule that selectively engages SHP1 Cys102.
• Structural and Biophysical Characterization:
  • Covalent Docking & MD Simulations: Modeled SCA1 binding to active vs. inactive SHP1 conformations.
  • HDX-MS (Hydrogen/Deuterium Exchange): Probed structural dynamics of SHP1 upon SCA1 binding to confirm conformational changes.
  • Intact Protein MS & Peptide Mapping: Confirmed specific covalent modification of Cys102.
• Functional Validation:
  • Assessed phosphatase activity in vitro.
  • Analyzed signaling pathways (TLR4/IRAK1/NF-κB) and cytokine production (IL-6, TNF, IL-1β) in mouse (iBMDMs) and human (THP-1, primary monocytes) macrophages.
  • Tested efficacy in monocytes derived from patients with Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS).

3. Key Contributions

• OxImmune Compendium: Created a comprehensive, publicly available resource (https://oximmune-chouchani-lab.dfci.harvard.edu/) mapping 788 dynamically redox-regulated cysteines across 1,125 immune-relevant proteins. This serves as a roadmap for targeting the "redox proteome."
• Novel Mechanism of SHP1 Activation: Discovered that SHP1 can be activated not by inhibiting its active site, but by covalently modifying a specific redox-switch cysteine (Cys102). This modification relieves auto-inhibition by destabilizing the N-SH2 domain's blockage of the active site.
• Development of SCA Series: Developed SCA1 and optimized analogs (SCA9, SCA7, SCA25) as highly selective, covalent agonists of SHP1. These molecules show proteome-wide selectivity for SHP1 Cys102 with minimal off-target engagement.
• Therapeutic Proof-of-Concept: Demonstrated that activating SHP1 via this redox switch effectively suppresses pro-inflammatory cytokine production in macrophages and monocytes from autoimmune disease patients.

4. Key Results

• Redox Landscape: ~6% (830) of mapped cysteines on immune proteins are dynamically redox-regulated. ~95% of these map to established functional domains (active sites, allosteric sites, protein-protein interfaces).
• SCA1 Specificity: SCA1 selectively labels SHP1 Cys102 at low micromolar concentrations (5–40 µM) in both human and mouse macrophages. It does not label the closely related phosphatase SHP2 or other cysteines with high stoichiometry.
• Structural Mechanism:
  • SCA1 binds to a pocket formed by the N-SH2 and C-SH2 domains near Cys102.
  • HDX-MS revealed that SCA1 binding stabilizes the N-SH2 domain while increasing flexibility in the C-SH2/PTP linker, consistent with a transition to the active conformation.
  • Molecular dynamics simulations confirmed that SCA1 binding is compatible with the active state but sterically clashes with the auto-inhibited state, suggesting it acts as a "conformational trap" for the active form.
• Signaling Inhibition:
  • SCA1 treatment prevents LPS-induced degradation of IκBα and phosphorylation of NF-κB p65.
  • It inhibits downstream STAT3 phosphorylation and reduces phagocytosis.
  • Cytokine Suppression: SCA derivatives (SCA9, SCA7, SCA25) potently inhibit LPS-induced production of IL-6, TNF, and IL-1β in macrophages (IC50 in single-digit micromolar range).
• Clinical Relevance:
  • Analysis of monocytes from RA and MS patients showed that Cys102 remains in a reduced (unmodified) state at baseline, making it accessible for covalent drug targeting.
  • Optimized SCAs significantly reduced pro-inflammatory cytokine secretion in monocytes from RA and MS patients upon LPS stimulation, without affecting baseline levels.

5. Significance

• Paradigm Shift in Drug Discovery: This work establishes a new strategy for drug discovery: systematically mapping in vivo redox-regulated cysteines to identify "druggable switches" that can be targeted by covalent agonists.
• Solving the "Undrugged" Phosphatase Problem: It provides a successful blueprint for developing positive allosteric modulators for protein phosphatases, a class historically difficult to target therapeutically.
• Therapeutic Potential for Autoimmunity: By demonstrating that SHP1 activation via Cys102 modulation suppresses inflammation in human autoimmune patient cells, the study validates a novel therapeutic avenue for Rheumatoid Arthritis, Multiple Sclerosis, and other TLR-driven inflammatory diseases.
• Resource for the Field: The OxImmune database provides the community with a foundational resource to identify similar redox switches on other immune proteins, accelerating the development of next-generation immunomodulators.